Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics.

about

Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics.

Item

http://www.wikidata.org/entity/Q49881176

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Practical considerations in cl ...... nation products for biologics.

@en

Practical considerations in cl ...... nation products for biologics.

@nl

type

Item

label

Practical considerations in cl ...... nation products for biologics.

@en

Practical considerations in cl ...... nation products for biologics.

@nl

prefLabel

Practical considerations in cl ...... nation products for biologics.

@en

Practical considerations in cl ...... nation products for biologics.

@nl

P1476

Practical considerations in cl ...... ination products for biologics

@en

P2093

Rachael Easton

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

P2860

Protein aggregation and its impact on product quality

Analytical lessons learned from selected therapeutic protein drug comparability studies.

Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.

An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects

Evaluation of the effect of syringe surfaces on protein formulations.

Nearly pain-free self-administration of subcutaneous methotrexate with an autoinjector: results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitations

Current and future issues in the manufacturing and development of monoclonal antibodies.

Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration.

The challenge of biosimilars.

Comparability and biosimilarity: considerations for the healthcare provider.

P304

18-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/19420862.2017.1392424

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Zhaoyang Li

P577

2017-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29035675

http://www.w3.org/2001/XMLSchema#string

P921

biomedical investigative technique

P932

5800388

http://www.w3.org/2001/XMLSchema#string